Navigation Links
Cempra Holdings, LLC Files Registration Statement for Proposed Initial Public Offering
Date:10/12/2011

CHAPEL HILL, N.C., Oct. 12, 2011 /PRNewswire/ -- Cempra Holdings, LLC, the parent holding company of Cempra Pharmaceuticals, Inc., today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to its proposed initial public offering.

Stifel Nicolaus Weisel, Leerink Swann LLC and Cowen and Company are serving as joint book-running managers for the offering. Needham & Company, LLC is acting as co-manager.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This news release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to and describing the terms of the offering may be obtained from Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by calling (415) 364-2720; Leerink Swann LLC, One Federal Street, 37th Floor, Boston, Massachusetts 02110, or by calling (800) 808-7525; or Cowen and Company, LLC c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, New York 11717, Attn: Prospectus Department, or by calling (631) 274-2806.

About Cempra Pharmaceuticals

Founded in 2006, Cempra Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical unmet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and skin and skin structure infections. Our two lead product candidates have both completed oral Phase 2 clinical trials and seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to use its proprietary macrolide library and chemistry technology to develop novel macrolides without antibacterial activity for non-antibiotic uses such as inflammatory and GI disorders. Additional information about Cempra can be found at www.cempra.com.

Contact:
Dr. Prabhavathi Fernandes
President and Chief Executive Officer
pfernandes@cempra.com
(919) 467-1716

Tony Russo, Ph.D.
Russo Partners, LLC
(212) 845-4251
Tony.russo@russopartnersllc.com


'/>"/>
SOURCE Cempra Holdings, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
2. Cempra Announces Comparable Efficacy of Oral Solithromycin (CEM-101) Compared with Levofloxacin in Phase II Clinical Trial in Patients with Community-Acquired Bacterial Pneumonia (CABP)
3. Cempra Pharmaceuticals to Present at the 2011 Wells Fargo Healthcare Conference
4. Cempra Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
5. Cempra Pharmaceuticals to Present at Two Investor Conferences in Paris
6. Intravenous (IV) Administration of Cempra Pharmaceuticals Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial
7. Cempra Pharmaceuticals to Present at Two Upcoming Cambridge Healthtech Institute (CHI) Conferences
8. Cempra Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Cempra Expands Clinical Management Team to Advance Leading Antibacterial Clinical Programs Solithromycin and TAKSTA™
10. Cempra Pharmaceuticals Names Carl Foster Executive Vice President of Business Development
11. Cempra Pharmaceuticals Names Richard Kent, M.D., to Its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... 2017  Andre, DiMino, CEO of ADM Tronics Unlimited, ... innovative technologies and products, commented on ADMT,s third quarter ... 2017 in the Company,s quarterly report on Form 10Q ... Andre, DiMino stated "During the quarter ended December 31, ... a larger portion of our engineering efforts into the ...
(Date:2/22/2017)... Summary Provides understanding and ... agreements entered into by the worlds leading healthcare ... Description The Global Myocardial Infarction Partnering ... partnering deals and agreements entered into by the ... in partnering deals - Top deals by ...
(Date:2/22/2017)... Summary Provides understanding and ... and agreements entered into by the worlds leading ... http://www.reportlinker.com/p03605673-summary/view-report.html Description The Global Congestive Heart ... access to partnering deals and agreements entered into ... - Trends in partnering deals - Top ...
Breaking Medicine Technology:
(Date:2/22/2017)... HEIGHTS, MICHIGAN (PRWEB) , ... February 22, 2017 ... ... and analysis of issues related to spine practices, is featuring Michigan neurosurgeon Jay ... is known as one of a small number of neurosurgeons in Michigan performing ...
(Date:2/22/2017)... , ... February 22, 2017 , ... A product of ... seem to derive a heart-protective benefit from eating soy foods, while others do not, ... men who are able to produce equol—a substance made by some types of “good” ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... percent of those report that family members or friends have also commented about ... from hearing loss wear hearing aids. One reason, suggested by 89 percent of ...
(Date:2/22/2017)... ... February 22, 2017 , ... Super-Sod will attend the ... event in Athens, Georgia. , A shift from Super-Sod’s simple Athens Home Show booth ... For the booth, grass seed plant manager Chris Roquemore constructed furniture from recycled pallet ...
(Date:2/22/2017)... ... ... Social media marketing is transitioning from a singular person activity to a ... into this insight and more in its latest episode of its Brains Over Brawn ... with social media strategist and partner of the digital firm Med|Ed Digital Jessica Columbo. ...
Breaking Medicine News(10 mins):